GlassScriptPhysician profile
Jonathan A Kistler
NPI 1033161740
$7,836.68
in general payments reported to CMS, 2019-2025
16 companies · $1,587 in 2025
The $1,587 reported for 2025 was more than what 87% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,760 · 2020: $888 · 2021: $1,290 · 2022: $1,079 · 2023: $453 · 2024: $779 · 2025: $1,587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,820.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $2,313.81 | 2019-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $1,253.07 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Janssen Pharmaceuticals, INC | $665.56 | 2019-2025 | Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $660.92 | 2020-2025 | Uzedy, Austedo Xr |
| Neurocrine Biosciences, INC. | $642.27 | 2019-2025 | Ingrezza |
| Sunovion Pharmaceuticals INC. | $598.26 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $406.86 | 2020-2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $376.09 | 2019-2022 | |
| Axsome Therapeutics, INC. | $282.46 | 2024-2025 | Auvelity |
| Lundbeck LLC | $240.18 | 2020-2024 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $148.15 | 2025 | Cobenfy |
| Indivior INC. | $146.42 | 2019-2024 | Perseris |
| Abbvie INC. | $34.97 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.42 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $23.40 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Pharmaceuticals, INC. | $17.84 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Kistler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.